Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 67.03 |
| Open | 66.59 |
| Bid | 67.07 x 400 |
| Ask | 67.11 x 400 |
| Day's range | 66.36 - 67.18 |
| 52-week range | 65.90 - 87.87 |
| Volume | |
| Avg. volume | 7,190,954 |
| Market cap | 83.647B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (4.59%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
- PR Newswire
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit"
- PR Newswire
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis C, hepatitis B, and hepatitis D in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon from 9
